Navidea biopharmaceuticals announces resignation of jed a. latkin

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the resignation of jed a. latkin as chief executive officer, chief financial officer and chief operating officer of the company, and as a member of the board of directors of the company, effective october 24, 2021. mr. latkin and the company are discussing the terms of
NAVB Ratings Summary
NAVB Quant Ranking